

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

ACHIRON Anat, et al

Serial No.: Not Yet Known

Filed: Concurrently

For: Peripheral Blood Cell Markers Useful For Diagnosing Multiple Sclerosis and Methods and Kits Utilizing Same

Examiner:

www.pearsoned.com

Group Art Unit:

Attorney
Docket: 28594

PETITION TO REVIVE UNINTENTIONALLY ABANDONED
APPLICATION UNDER 37 CFR 1.137

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

09/28/2004 LLANDGRA 00000026 10507380

01 FC:1453

Sir: 1330.00 DP

The above-identified application became abandoned on September 21, 2004 for failure to enter the National Stage as a 35 U.S.C. 371 filing within thirty (30) months of the March 21, 2002 priority date of PCT Application No. PCT/IL03/00208.

Applicant hereby petitions for revival of this application.

A submission under 35 U.S.C. 371 is attached herewith.

Please charge the petition fee under 37 CFR 1.17(m) in the amount of \$1,330

The entire one day delay in filing the National Stage Application until the filing of this grantable petition was unintentional, and was due to a delayed delivery of this application by Federal Express.

RECEIVED

11 MAY 2005


**Legal Staff
International Division**

BEST AVAILABLE COPY

Authorization to charge the above petition fee of \$1,330 to the Credit Card number listed on the attached Credit Card Payment Form PTO-2038 is attached herewith. In the event additional fees are required, please charge these additional fees to Deposit Account 50-1407. In the unlikely event payment by the Credit Card issuer is refused, please charge the petition fee of \$1,330 to Deposit Account 50-1407.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Respectfully submitted,



Martin Moynihan
Registration No. 40,338

Date: September 22, 2004